Nonclinical Efficacy Testing » Non-Clinical CROs and Agencies » Yecuris Corporation

Yecuris Corporation

Table of Contents
Table of Contents

Yecuris supplies liver-humanized mice and human hepatocytes from a facility in the Portland area of Oregon, and runs studies on that platform.[S1][S2] The central asset is the FRG KO mouse, an immunodeficient animal whose own liver cells are progressively replaced by transplanted human hepatocytes; the company states that livers are more than 70% repopulated with human cells.[S2] The same donor hepatocytes are also sold for use in culture, which the company presents as its distinguishing feature: one donor, used both in an animal and in a dish.[S5][S10] The company was founded by Dr. Markus Grompe using technology from his laboratory at Oregon Health & Science University.[S1]

What the company conducts, and what it does not

The company describes its own position inconsistently, and this matters when deciding what can be placed here. The home page tagline reads "Liver Humanized Mice and CRO Services".[S10] The about page instead offers to work with the client, with the client's preferred contract research organization, or through a network of providers.[S1] The infectious disease page is explicit that studies to a client's specification are completed through partner organizations rather than in-house.[S7] Read together, the reasonable interpretation is a platform and model supplier that also conducts work on its own platform, with some study types routed to partners. A sponsor should establish which category a specific study falls into, and where it will physically be performed, before contracting.

The platform

FRG KO liver-humanized mice

The FRG designation refers to a triple knockout of Fah, Rag2 and Il2rg on a C57BL/6 background, which the company states was originally reported by Azuma and colleagues in 2007.[S2] The first of those deletions makes the mouse's own hepatocytes dependent on a protective drug; withdrawing it creates the selective pressure under which transplanted human cells expand, and the company describes engraftment as sustained over the animal's life with continued dosing of that reagent.[S2] The other two deletions remove the immune compartments that would otherwise reject human cells. Animals are described as housed and shipped from a barrier facility in Portland, Oregon.[S2] Custom transplantation is offered using any donor and any species, alongside custom generation of liver-humanized animals.[S9]

HepaCur human hepatocytes

Primary human hepatocytes that have been passaged through the mouse are sold fresh or cryopreserved.[S5] The practical consequence, which the company states directly, is that the same donor cells can be used in vivo and in vitro.[S10] For a programme that runs a cell assay and an animal study on the same question, that removes one variable, since a difference between the two results cannot be attributed to donor difference. Whether it removes the more important variables is a separate question this profile does not address.

Application areas, as described by the company

Drug metabolism and pharmacokinetics is the longest-standing use, and the company publishes worked examples on named compounds including propafenone, midazolam, lamotrigine and diclofenac, plus one on lipoprotein production.[S4] Gene and cell therapy work is framed as screening a delivery vehicle or payload in the hepatocytes first and validating in the animal afterwards, including screening of adeno-associated virus serotypes.[S6] Hepatotropic infection work covers malaria and viral hepatitis B, C and E, routed through partner organizations.[S7] Steatohepatitis models are diet-induced on the humanized background, with metabolic monitoring of body weight, food consumption, cholesterol, glucose and insulin, and pathology reported with the activity score and fibrosis stage.[S8] Toxicology appears in the company's own list of service areas but no dedicated page or named study type was found for it.[S1]

Quality, compliance, and animal welfare

No statement about good laboratory practice, AAALAC International accreditation, USDA registration, an OLAW Animal Welfare Assurance, or an institutional animal care and use committee was found on any of the ten pages reviewed for this profile.[S1][S2][S9] The only related language located was a description of animals as pathogen free and of the facility as a barrier facility, with no named accrediting or registering body.[S2] This is an absence of published disclosure on the pages found, not a finding about the company's internal arrangements, and a dedicated quality page may exist that was not located. It is worth noting because the company conducts in-life animal work at its own facility, and because most other profiles on this site were able to record at least one such statement. AAALAC International accreditation is a voluntary evaluation of an institution's animal care and use program, re-evaluated every three years,[R3] and USDA registration and an OLAW Animal Welfare Assurance relate to the Animal Welfare Act and the PHS Policy respectively;[R4][R5] none of these establishes GLP compliance, which applies to individual studies.[R2] FDA does not approve or certify laboratories; registration with FDA does not denote approval.[R6] A sponsor whose study needs to be conducted under the good laboratory practice regulation should treat this as the first question to settle, not the last.[R2]

Ownership, leadership, and unresolved details

The company became part of the Janvier Group, based in France, on January 30, 2024, with existing management retained: Rob Copenhaver as chief executive, Patrick Duong as director of finance, and Dr. Devorah Goldman as scientific director.[S3] Two details could not be resolved. The company gives no explicit founding year; a statement that organizations have used its tools since 2007 may describe when the technology became available rather than when the corporation was formed.[S1] And the location is given two ways: the about page lists only a post office box in Tualatin, Oregon, while the acquisition announcement hosted on the same site describes operations continuing from a Portland location.[S1][S3] No employee count was found on any page reviewed.[S1]

Company facts

Legal nameYecuris Corporation[S1]
HeadquartersStated two ways: a post office box in Tualatin, Oregon on the company's about page, and a Portland, Oregon location in the acquisition announcement[S1][S3]
FoundedNo explicit founding year published; the company states clients have used its tools since 2007[S1]
FounderDr. Markus Grompe, using technology from his laboratory at Oregon Health & Science University[S1]
OwnershipPart of the Janvier Group, based in France, since January 30, 2024[S3]
LeadershipRob Copenhaver, chief executive; Patrick Duong, director of finance; Dr. Devorah Goldman, scientific director[S3]
EmployeesNot published
RevenueNot published
SitesOne facility in the Portland area of Oregon; own facility since 2013, doubled in size in 2016[S1][S2]
Core platformFRG KO liver-humanized mouse; Fah, Rag2 and Il2rg triple knockout on C57BL/6; company states more than 70% human hepatocyte repopulation[S2]
Cell productHepaCur mouse-passaged primary human hepatocytes, fresh or cryopreserved[S5]
Application areasDrug metabolism and pharmacokinetics, gene and cell therapy, hepatotropic infection, steatohepatitis models, custom transplantation[S1][S4][S6][S7][S8][S9]
Work routed to partnersInfectious disease studies to client specification, stated as completed through partner organizations[S7]
GLPNo statement found on the pages reviewed
AAALAC, USDA, OLAW, IACUCNo statement found on any of the ten pages reviewed
Websiteyecuris.com

References

  1. Yecuris ? About Us. https://www.yecuris.com/about-us-2/ (accessed 2026-09-03)
  2. Yecuris ? FRG KO Mice. https://www.yecuris.com/frg-ko-mice/ (accessed 2026-09-03)
  3. Yecuris ? Janvier Group acquisition announcement(2024-1-30). https://www.yecuris.com/yecuris_janvier/ (accessed 2026-09-03)
  4. Yecuris ? DMPK. https://www.yecuris.com/dmpk-2/ (accessed 2026-09-03)
  5. Yecuris ? Fresh Hepatocytes (HepaCur?). https://www.yecuris.com/fresh-hepatocytes/ (accessed 2026-09-03)
  6. Yecuris ? Gene and Cell Therapy. https://www.yecuris.com/gene-and-cell-therapy-2/ (accessed 2026-09-03)
  7. Yecuris ? Infectious Diseases. https://www.yecuris.com/infectious-diseases/ (accessed 2026-09-03)
  8. Yecuris ? NASH. https://www.yecuris.com/nash/ (accessed 2026-09-03)
  9. Yecuris ? Research Services. https://www.yecuris.com/research-services/ (accessed 2026-09-03)
  10. Yecuris ? home. https://www.yecuris.com/ (accessed 2026-09-03)
  11. 21 CFR Part 58 ? Good Laboratory Practice for Nonclinical Laboratory Studies (§58.1 scope; §58.3 definitions; §58.35 quality assurance unit), eCFR. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-58 (accessed 2026-09-03)
  12. AAALAC International ? FAQs ("voluntary accreditation program"; re-evaluation every three years). https://www.aaalac.org/accreditation-program/faqs/ (accessed 2026-09-03)
  13. USDA APHIS ? Animal Welfare Act: research facilities must obtain a registration; Animal Care inspections. https://www.aphis.usda.gov/awa/public-search (accessed 2026-09-03)
  14. Public Health Service Policy on Humane Care and Use of Laboratory Animals (Animal Welfare Assurance submitted to NIH OLAW). https://grants.nih.gov/policy-and-compliance/policy-topics/animal-welfare/laws-regulations/phs-policy (accessed 2026-09-03)
  15. FDA ? "Is It Really FDA Approved?" (FDA does not approve health care providers, including laboratories; registration does not denote approval); FDA Compliance Program 7348.808 (GLP inspections of nonclinical laboratories). https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved (accessed 2026-09-03)

3 Recommended Contract Research Organizations
for Non-Clinical Studies
— by Target goal and Expertise

In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.

Pharmacology (Efficacy) StudiesDisease-Relevant Models for
Translational Drug Evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/)

SMC Laboratories, Inc.

SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.

Areas of Expertise
Disease-Relevant Model Portfolio

SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.

Study Design Based on Target Biology

Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.

Support from Target Validation to Proof of Concept

With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.

Safety StudiesComprehensive Safety Assessment for
Preclinical Development
Charles River Laboratories
Reference: Charles River Laboratories official website (https://www.criver.com/)

Charles River Laboratories

Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.

Areas of Expertise
General Toxicology Across Study Designs

Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.

Non-GLP and GLP Study Support

Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.

Integrated IND-Enabling Safety Assessment

Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.

Pharmacokinetic (PK/PD) StudiesConnecting Drug Exposure with
Pharmacological Response
Inotiv
Reference: Inotiv official website (https://www.inotiv.com/)

Inotiv

Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.

Areas of Expertise
Pharmacokinetic Characterization

PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.

Exposure–Response Evaluation

Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.

Integrated DMPK and Development Support

Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.

By Therapeutic Area
Disease Animal Models
and Reviews
Proven Capability, Expertise and Track Record
Top 3 Non-Clinical CRO Services